Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) and to
establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules,
namely, intermittent, weekly, and continuous in patients with advanced solid tumors or
lymphoma, namely, intermittent, weekly, and continuous.